Insilico Medicine (HKG:3696) said it entered a drug development partnership with China Medical System (HKG:0867, SGX:8A8), according to a Hong Kong bourse filing Tuesday.
Under the agreement, the two sides will collaborate to co-develop at least two drugs.
Insilico Medicine is expected to receive R&D funding support of up to "several tens of millions of HKD" for each program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.